thiazoles has been researched along with Peritoneal Carcinomatosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cominetti, D; De Cesare, M; Deraco, M; Doldi, V; Friedlander, S; Gandellini, P; Kauffman, MG; Landesman, Y; Lopergolo, A; Pennati, M; Shacham, S; Zaffaroni, N | 1 |
| Fujimura, T; Fujita, H; Fushida, S; Harada, S; Hirakawa, K; Kayahara, M; Kinoshita, J; Kinuya, S; Ninomiya, I; Ohta, T; Oyama, K; Tsukada, T; Yagi, Y; Yashiro, M | 1 |
| Alpaugh, RK; Brady, WE; Fiorica, JV; Godwin, AK; Hu, W; Lankes, HA; Mannel, RS; Pathak, HB; Schilder, RJ; Shahin, MS; Sood, AK; Zhou, XC | 1 |
| Dickson, RB; Kanayama, N; Kobayashi, H; Lin, CY; Saga, Y; Suzuki, M; Terao, T | 1 |
| Futagami, M; Mizunuma, H; Shigeto, T; Xin, B; Yokoyama, Y | 1 |
| Mizunuma, H; Shigeto, T; Xin, B; Yokoyama, Y | 1 |
1 trial(s) available for thiazoles and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Dasatinib; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Thiazoles | 2012 |
5 other study(ies) available for thiazoles and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Exportin 1 Protein; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazines; Inhibitor of Apoptosis Proteins; Karyopherins; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, SCID; Neoplasm Proteins; Oxadiazoles; Peritoneal Neoplasms; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Survivin; Thiazoles; Triazoles; Tumor Suppressor Protein p53 | 2015 |
Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Blotting, Western; Cell Line, Tumor; Coloring Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Iodine Radioisotopes; Mice; Mice, Inbred BALB C; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tetrazolium Salts; Thiazoles; Tissue Distribution; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Topics: Animals; Binding, Competitive; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Membrane; Coloring Agents; Culture Media, Conditioned; DNA, Complementary; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Matrix; Fibrinolysin; Flow Cytometry; Genome; Humans; Membrane Glycoproteins; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Oligonucleotides, Antisense; Peritoneal Neoplasms; Protein Binding; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Recombinant Proteins; Serine Endopeptidases; Tetrazolium Salts; Thiazoles; Time Factors; Transfection; Transforming Growth Factor beta; Transforming Growth Factor beta1; Trypsin Inhibitor, Kunitz Soybean; Urokinase-Type Plasminogen Activator | 2004 |
Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Topics: Animals; Apoptosis; Ascites; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Immunohistochemistry; Intramolecular Oxidoreductases; Meloxicam; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Peritoneal Neoplasms; PPAR gamma; Prostaglandin-E Synthases; Survival Analysis; Thiazines; Thiazoles; Thiazolidinediones; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.
Topics: Animals; Aspirin; Carcinoma; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Meloxicam; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Peritoneal Neoplasms; Piroxicam; Thiazines; Thiazoles; Xenograft Model Antitumor Assays | 2007 |